TrialThe Lancet. Haematology2022

Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.

David I Marks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.